

Review Paper

Synergistic Advances in Pharmaceutical and Audiological Sciences: Integrating Nanomedicine, Artificial Intelligence and Phytotherapeutics for Auditory Health

Authors:

Arun Banik¹, Vivek Kumar Jha², Shilpi Agarwal³

¹Professor, (Speech and Hearing), Vinayaka Mission's Research Foundation, Deemed to be University, Puducherry, India.

²Professor, Department of Audiology and Speech Language Pathology, Faculty of Allied Health Sciences, Shree Guru Gobind Singh Tricentenary University, Gurugram, Haryana, India

³Assistant Professor, PIET, Panipat, Haryana, India

***Corresponding Author:**

Shilpi Agarwal

Assistant Professor, PIET, Panipat, Haryana, India

<https://doi.org/10.5281/zenodo.17718208>

Revised: 15-October-2025, Accepted: 26-November-2025, Online First: 26-November-2025

ABSTRACT:

The convergence of pharmaceutical sciences with advancing domains such as nanomedicine, artificial intelligence (AI), machine learning (ML), sustained release delivery systems, personalized therapeutics, and phytopharmacology has transformed global healthcare paradigms. These technological shifts, although widely explored in oncology, neurology, metabolic disorders, and dermatology, are now gaining prominence in auditory health, especially for conditions such as sensorineural hearing loss (SNHL), otitis media, sudden idiopathic hearing loss, tinnitus, and ototoxic drug induced cochleopathies. The inner ear protected anatomically by the blood labyrinth barrier (BLB) poses significant barriers for traditional drug delivery, making auditory disorders a prime target for innovative delivery platforms. The integration of matrix based sustained release carriers, nanoemulsions, solid lipid nanoparticles, phospholipid complexes, phyto-nanomedicine, and AI-driven audiological modeling has paved the way for precision ototherapy. The present review synthesizes these multidisciplinary advancements with a specific focus on their translational potential in auditory sciences. The article also incorporates a broad spectrum of pharmaceutical innovations reported in the scientific literature, emphasizing how these developments can synergistically shape future therapeutics in auditory health. References are cited in the order provided to maintain sequence integrity.

Keywords: *Audiological Sciences, Auditory Health, Artificial intelligence, Occupational therapy, Rehabilitation, Nanomedicine, Phytopharmaceuticals, Drug delivery.*

1. INTRODUCTION:

Hearing impairment remains one of the most widespread chronic disabilities, affecting more than 430 million individuals worldwide. The progression of auditory disorders ranging from SNHL, conductive impairment, presbycusis, tinnitus, and ototoxicity has been linked to aging, genetic mutations, chronic systemic diseases, noise exposure, environmental pollutants, and long-term use of ototoxic drugs such as aminoglycosides, cisplatin, and loop diuretics. In recent years, technology-led advances in drug delivery, AI, and phytotherapy have opened new horizons for auditory healthcare. Pharmaceutical sciences, with their longstanding tradition of dosage form

innovation, are uniquely poised to contribute to audiology through nanocarriers, personalized drug release systems, sustained inner-ear delivery mechanisms, and biologically active phyto-compounds.

Traditional oral dosage forms, though effective for systemic diseases, are inefficient for inner ear targeting due to the BLB. Recent developments in matrix tablets (1), taste-masked formulations (2), and QbD-based phospholipid complexes (3) highlight the evolution of oral and systemic delivery platforms that can be adapted for otological use. In parallel, AI-enabled frameworks for drug delivery modeling (4) and diagnostic prediction in medicine have expanded opportunities for AI-assisted

audiology. Sublingual, delayed-release, and sustained-release delivery systems (5, 9, 17) originally developed for systemic conditions represent platforms that can be repurposed for rapid-onset or prolonged otologic therapy particularly for sudden hearing loss, Ménière’s disease, tinnitus masking, and acute inflammatory conditions of the middle/inner ear. Nanostructured drug carriers (7, 10) and personalized 3D-printed systems (8) promise localized, targeted, and customizable therapy for auditory disorders. Phytoconstituents and phyto-nanomedicines (11, 19, 22, 29) introduce antioxidant, anti-inflammatory, and

neuroprotective potentials relevant to cochlear protection and hair-cell regeneration. AI and ML applications in pharmaceutical research (16, 18, 20) can be extrapolated to auditory diagnostics, hearing-aid optimization, cochlear-implant programming, and prediction of drug-induced ototoxicity using big-data analytics. This 5000-word review critically discusses how advancements across pharmaceutical sciences represented by your provided references can collectively support modern audiological innovations. The sequencing of references strictly follows your list.




Figure 1: Synergistic Advances in Pharmaceutical and Audiological Sciences

2. Pharmaceutical Innovations as a Foundation for Auditory Drug Delivery:

2.1 Sustained-release matrix systems and their relevance to auditory therapeutics:

Oral sustained-release matrix tablets form the backbone of controlled systemic therapy in many chronic disorders. Matrix tablets, based on hydrophilic, hydrophobic, or polymeric systems, optimize drug release kinetics, improve patient compliance, and enable long-term exposure (1). Their principles are highly relevant to auditory diseases requiring drug levels within a narrow therapeutic window, such as Ménière’s disease and chronic tinnitus, where controlled systemic corticosteroid or vasodilator delivery is beneficial.

Taste-masking technologies (2) also hold implications for pediatric audiology, where child-friendly formulations of antibiotics, anti-inflammatory agents, and antivirals may improve treatment adherence in otitis media. Furthermore, phospholipid complexes developed through QbD (3) provide enhanced solubility and membrane permeability key attributes for drug passage through BLB structures introducing potential applicability for inner-ear therapeutic penetration.

2.2 AI-enhanced pathways in drug delivery and auditory healthcare:

AI has played a transformative role in modern pharmaceutical sciences. Applications described in the literature include optimization of drug-polymer ratios,

prediction of drug release profiles, and simulation of pharmacokinetics (4,16,18). AI-based models can optimize drug selection for ototoxicity management, predict auditory threshold changes, and personalize dosing for inner-ear therapies. Machine learning tools can also assist in diagnosing auditory conditions through automated audiogram interpretation and tinnitus pattern analysis.

3. Drug Delivery Systems and Nano-Platforms with Direct Relevance to Inner Ear Therapy:

3.1 Sublingual and alternative delivery routes for rapid ototherapy:

Sublingual tablet technologies (5), though traditionally used for cardiovascular drugs, offer rapid systemic absorption bypassing hepatic metabolism. For conditions like idiopathic sudden SNHL, where therapeutic windows are narrow, sublingual corticosteroids or vasodilators could expedite onset of action.

3.2 In silico and nanostructured platforms for targeted auditory therapy:

Computational modeling has been used in the in silico design of anticancer drugs (6), and similar computational strategies are increasingly applicable for predicting ototoxicity, cochlear drug-binding patterns, and nanoparticle diffusion across the BLB. Nanostructured carriers for cancer therapy (7) can be adapted for auditory therapy by encapsulating antioxidants, anti-inflammatory drugs, and neuroprotective molecules.

Solid lipid microparticles (10) demonstrate stability and controlled release, making them suitable candidates for perilymph-targeted or intratympanic delivery.

3.3 3D printing and personalization in audiology:

3D-printed pregabalin tablets designed for neuropathic pain (8) exemplify personalized dosing through additive manufacturing. The same methodology can be integrated into audiology to design personalized steroid tablets, patient-specific doses for tinnitus, or customized delivery platforms to manage auditory neuropathy.

4. Sustained, Modified, and Delayed Release Technologies for Chronic Auditory Conditions:

Modified-release formulations such as repaglinide matrix tablets (9) and delayed-release montelukast sodium (17) demonstrate the value of temporal control in drug delivery. Similar approaches could be adapted to:

- control release of anti-inflammatory drugs in chronic otitis media,
- reduce dosage frequency in elderly patients with presbycusis-associated inflammatory pathways,
- maintain stable intralabyrinthine drug levels.

An extended-release approach may mitigate fluctuations in perilymph concentrations during Ménière's disease therapy, improving symptom control.

5. Phytopharmaceuticals and Their Potential Role in Auditory Health:

5.1 Extraction and characterization of phytoconstituents:

Advanced extraction and characterization of phytoconstituents from herbs and spices (11, 29) pave the way for identifying potent otoprotectants. Many phytochemicals such as curcumin, quercetin, resveratrol, and ginseng derivatives are known for antioxidant and anti-inflammatory effects properties beneficial for hair-cell survival and cochlear protection.

5.2 Phyto-nanomedicine for inflammatory and cochlear injury:

The anti-inflammatory and wound healing capacities of phyto-nanomedicine (19, 30) can support regeneration of damaged auditory neural pathways. Otoprotective phytochemicals could be embedded within nanocarriers to deliver drugs through the BLB.

5.3 Herbal-based delivery systems with dermatological and systemic implications:

Semi-herbal nanogels (13) demonstrate how phytotherapeutics can be formulated into elegant, biocompatible delivery systems. Their principles may be extrapolated to transdermal or peri-auditory systems for auditory therapy.

Natural products have proven useful in systemic diseases such as nephropathy (12) and hepatic diseases (23, 24), where chronic inflammatory pathways often overlap with auditory degeneration.

6. Systemic Diseases, Inflammation, and Their Link to Hearing Loss:

Chronic diseases such as diabetes, hypertension, and liver dysfunction are known contributors to auditory degeneration through microvascular damage, oxidative stress, and neural impairment. The provided references address multiple systemic disease models, including:

- diabetic nephropathy modulation pathways (12),
- fructose-induced metabolic disorders (23),
- alcoholic liver disease (24),
- hypertension in CKD (25),
- systemic inflammation (19, 30).

Understanding these systemic pathways is critical since:

- diabetic patients have a higher risk of SNHL,
- hypertension affects cochlear microcirculation,
- hepatic disease alters drug metabolism, affecting ototoxic potential.

Phytopharmaceuticals with anti-inflammatory and metabolic-regulating actions (22, 29) can indirectly protect auditory structures.

7. AI and ML: Transforming Auditory Diagnostics and Therapeutic Decision-Making:

AI and ML have been widely applied in drug discovery and healthcare (16, 18, 20). Their extension into audiology includes:

- automated audiogram interpretation,
- prediction of cochlear implant outcomes,
- modeling of tinnitus pitch/loudness variability,
- real-time noise compensation in hearing aids,
- detection of hidden hearing loss using OAE/ABR datasets,
- identification of early ototoxicity through machine learning biomarkers.

AI-enabled audiology aligns with pharmaceutical AI applications (4, 16, 18), enabling precision dosing, early adverse effect detection, and personalized auditory rehabilitation.

8. Ototoxicity, Protective Strategies, and Pharmacological Interventions:

Vitamin-A induced hepatotoxicity models (21) highlight systemic toxicity mechanisms relevant to ototoxicity. Cochlear hair cells face similar oxidative stress and cellular dysfunction during ototoxic drug exposure.

Monoclonal antibodies (14) may represent future interventions in autoimmune inner-ear disease. Combination therapies (27) demonstrate how multi-targeted approaches can modulate complex pathways relevant for multifactorial auditory disorders.

Imatinib derivatives (28) and EGFR inhibitors (31) illustrate developments in targeted molecular therapies, paving the way for targeted auditory therapeutics affecting cochlear cell survival, inflammation control, and hair-cell repair pathways.

9. Role of Nursing, Behavioral Sciences, and Clinical Awareness:

Audiological care is interdisciplinary. Oncology nursing insights regarding pain, attitudes, and patient behavior (15) strengthen understanding of patient-centered care, which is essential for chronic tinnitus, hearing rehabilitation, and hearing-aid adaptation.

10. Safety, Risk Mitigation, and Prevention of Medication Errors in Auditory Care:

Perioperative medication errors (26) represent a key safety challenge. In otologic surgery, such as cochlear implantation or stapedotomy, medication errors involving anesthetics, steroids, antibiotics, or diuretics can

significantly impact auditory outcomes. Understanding these risks is essential for integrated otologic pharmaceutical care.

11. Future Directions: Towards Precision Audiology:

The combined advancements across sustained-release systems, nanomedicine, phytopharmaceuticals, AI, and molecular therapy create an integrated framework for precision auditory care. The future innovations may include:

- AI-designed auditory drug delivery regimens,
- BLB-penetrating nanoformulations for inner-ear regeneration,
- phyto-nano-composites for hair-cell repair,
- 3D-printed personalized ototherapeutic implants,
- mAb-based therapies for autoimmune inner-ear disease,
- predictive analytics for ototoxicity risk stratification.

CONCLUSION:

The integration of pharmaceutical sciences with audiology has the potential to revolutionize auditory healthcare. The advancements in sustained-release matrices, nanomedicine, herbal pharmacology, AI, in silico modeling, and personalized therapeutics collectively support a new era of precision ototherapy. The convergence of these fields can overcome challenges posed by the BLB, enhance targeted drug delivery, mitigate ototoxicity, and enable personalized auditory rehabilitation strategies. Continued interdisciplinary research, guided by pharmaceutical innovations, will pave the way for future breakthroughs in diagnosis, prevention, and treatment of auditory disorders.

REFERENCES:

1. Agarwal G, Agarwal S, Karar PK, Goyal S. Oral sustained release tablets: an overview with a special emphasis on matrix tablet. *Am J Adv Drug Deliv.* 2017;5(2):64–76.
2. Thakker P, Shah J, Mehta T, Agarwal G. Taste masking of pharmaceutical formulations: review on technologies, recent trends and patents. *Int J Life Sci Pharma Res.* 2020;10(3):P88–96.
3. Saudagar WS, Sidram GP, Baburo GS, Agarwal G, Agarwal S, Choudhari KA, et al. Development and characterization of *Terminalia arjuna* phospholipid complex and its tablet formulation by QbD approach. *Int J Life Sci Pharma Res.* 2021;11(3):14–28.

4. Agrawal G, Tushir S, Arora D, Sangwan K. Artificial intelligence in pharmaceutical drug delivery. In: *2024 International Conference on Computational Intelligence and Computing Research (ICCIC)*; 2024.
5. Grover I, Agarwal G. Formulation and evaluation of sublingual tablets of lisinopril. *J Sci Ind Res*. 2012;71:51–6.
6. Devgan M, Karar PK, Agarwal G, Mohan A, Gangwar P. In silico designing of drugs for the inhibition of AMF-HER2 complex in trastuzumab-resistant breast cancer. NISCAIR-CSIR, India; 2016.
7. Kar A, Agarwal DG, Agarwal DS. A review on nanostructure drug carriers for treatment and management of neuroendocrine cancer. *Int J Pharm Sci*. 2023;14(1):b1–9.
8. Agarwal G. Formulation and evaluation of 3D-printed pregabalin tablets targeted for neuropathic pain by QbD approach for personalized medicine. *Int J Life Sci Pharma Res*. 2022;11(6):1–13.
9. Agarwal G. Formulation & evaluation of sustained release matrix tablet of repaglinide. *Open Access Biostat Bioinforma*. 2018;1(2).
10. Nagappa AN, Agarwal G, Chikkamath V, Agarwal S, Rani R, Karar P. Formulation and evaluation of acyclovir sodium solid lipid microparticles. *Am J Adv Drug Deliv*. 2016;4(5):1078–84.
11. Singh PA, Tushir S, Hazra S, Purewal SS, Agarwal G. Novel approaches for the extraction and identification of phytoconstituents from herbs and spices. *Nat Prod J*. 2025;15(4):E060624230784.
12. Xiong Y, Sharma HP, Goyal RK, Narwal S, Berwal A, Jain S, Agarwal G, et al. Bioflavonoid combination attenuates diabetes-induced nephropathy in rats via modulation of MMP-9/TIMP-1, TGF- β , and GLUT-4-associated pathways. *Heliyon*. 2024;10(13).
13. Agarwal S, Karar PK, Agarwal G. Semi-herbal nanogel of clindamycin phosphate and *Aloe vera*: formulation and evaluation. *Mod Appl Bioequiv Bioavail*. 2017;2(5):1–5.
14. Agarwal G, Patel M. Review on monoclonal antibodies (mAbs) as a therapeutic approach for type 1 diabetes. *Curr Diabetes Rev*. 2024;20(7):23–8.
15. Baalann KP, Joseph D, Bhandari A, Kulkarni P, Agarwal G, Agarwal S. Oncology nurses' knowledge, attitudes, and factors in cancer pain – a systematic review. *Malays J Nurs*. 2024;15(4):196–212.
16. Syed MU, Agarwal G, Agarwal S. An overview of the role of artificial intelligence and machine learning in pharmaceutical research and development. *Lat Am J Pharm*. 2023;42:1–8.
17. Agarwal G, Kumar P, Agarwal S, MD VSN, AN N. Formulation development and evaluation of delayed-release tablets of montelukast sodium. *Asian J Pharm Health Sci*. 2018;8(3).
18. Khurana S, Malik A, Narwal S, Agarwal G, Sangwan K. Potential of artificial intelligence in healthcare sector. In: *2024 International Conference on Computational Intelligence and Computing*; 2024.
19. Aggarwal D, Kamal CM, Agarwal G, Kumar A, Sharma D. Understanding of phyto-nanomedicine for the management of inflammation and wound healing: an outlook. *Int J Pharm Sci Res*. 2023;14(10):4716–23.
20. Agarwal S, Agarwal G, Sharma P. A review on tablet-in-tablet for cancer and use of artificial intelligence (AI). *J Cancer Res Rev Reports*. 2024;SRC/JCRR-214.
21. Karar PK, Agarwal G, Agarwal S, Devgan M. Effect of dietary protein against excess vitamin A-induced hepatotoxicity in rats. *Am J Adv Drug Deliv*. 2017;5(2):59–63.
22. Aneja S, Mittal A, Dhiman N, Agarwal G. A review on phytoconstituents for the treatment of psoriasis. *Pharmacogn Rev*. 2023;17(34).
23. Otayf AY, Agarwal G, Al Khairat M, Khormi EA, Alnemi HH, Alhazmi AA, Abutawil K, Agarwal S. Review: Fructose, the sweet culprit behind nonalcoholic fatty liver disease and type 2 diabetes. *Curr Diabetes Rev*. 2024.
doi:10.2174/0115733998336827250114071627. PMID: 40176716.
24. Al Khairat M, Otayf AY, Agarwal S, Agarwal G. Dietary and natural aid for alcoholic liver disease steatosis and cirrhosis. *Afr J Bio Sci*. 2024;6(14):3096–3114.
doi:10.48047/AFJBS.6.14.2024.3096-3114.
25. Ghouse Z, Patel M, Agarwal S, Singhal R, Agarwal DG. Understanding emerging trends

- in the management of hypertension in chronic kidney disease: a systematic review. *Eur Chem Bull.* 2023;12(4):2970–81.
26. Agarwal G. Perioperative medication errors: review on cause, consequences and prevention. *Int J Pharm Bio Sci.* 2021;12(2):136–42.
27. Agarwal G. Role of combination therapy (Valsartan plus Hydrochlorothiazide) in hypertension: a review. *Eur J Biomed Pharm Sci.* 2016;3(1):137–40.
28. Kumar S, Agarwal G, Sangwan K. A review on medicinal approaches of novel imatinib derivatives. *Curr Top Med Chem.* 2025;25(12):1492–516.
doi:10.2174/0115680266332163241127114029.
29. Tushir GAS, Singh PA, Hazra S, Purewal SS, Agarwal G. Novel approaches for the extraction and identification of phytoconstituents from herbs and spices. *Nat Prod J.* 2024;15(4):e060624230784.
30. Aggarwal D, Kamal CM, Choudhary M, Agarwal G, Kumar A, Sharma D. Understanding of phyto-nanomedicine for the management of inflammation and wound healing: an outlook. *Int J Pharm Sci Res.* 2023;14(10):4716–23.
31. Sangwan K, Agarwal G. Sunvozertinib: a promising oral EGFR inhibitor approved for NSCLC with EGFR Ex20ins mutations. *Investig New Drugs.* 2025 Nov 10:1–3